# Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL

> **NCT04638270** · EARLY_PHASE1 · UNKNOWN · sponsor: **Xinqiao Hospital of Chongqing** · enrollment: 16 (estimated)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** anti-CD19 FasT CAR-T cells

## Key facts

- **NCT ID:** NCT04638270
- **Lead sponsor:** Xinqiao Hospital of Chongqing
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-21
- **Primary completion:** 2021-11-01
- **Final completion:** 2023-11-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2020-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04638270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04638270, "Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04638270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*